BJE6-106 (B106) is a potent, selective 3 rd generation PKCδ inhibitor with an IC 50 of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC 50 =50 μM). BJE6-106 (B106) induces caspase-dependent apoptosis . BJE6-106 (B106) possesses tumor-specific effect. In Vitro BJE6-106 (B106) (0.2 μM, 0.5 μM; 24-72 hours) suppresses cell survival in melanoma cell lines with NRAS mutations. BJE6-106 (B106) (0.2 μM, 0.5 μM; 6-24 hours) triggers caspase-dependent apoptosis, increases the activity of caspase 3/7, the effect of B106 is greater than rottlerin (10-fold) in SBcl2 cells. BJE6-106 (B106) (0.5 μM; 2-10 hours) activates the MKK4-JNK-H2AX Pathway by inducing MKK4, JNK and H2AX activation at different times in SBcl2 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Melanoma cell lines with NRAS mutations: SBcl2, FM6, SKMEL2, WM1366, WM1361A, and WM852 cells Concentration: 0.2 μM, 0.5 μM Incubation Time: 24 hours, 48 hours, or 72 hours Result: Inhibited cell survival in melanoma cell lines. Apoptosis AnalysisCell Line: SBcl2 cells Concentration: 0.2 μM, 0.5 μM Incubation Time: 6 hours, 12 hours, or 24 hours Result: Induced caspase 3/7 activation. Western Blot AnalysisCell Line: SBcl2 cells Concentration: 0.2 μM, 0.5 μM Incubation Time: 2 hours, 5 hours, 10 hours Result: Increased phosphorylation of MKK4, JNK and H2AX. Form:Solid IC50& Target:PKCδ 0.05 μM (IC 50 ) PKCα 50 μM (IC 50 )